Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment
Osteosarcoma, with poor survival after metastasis, is considered the most common primary
bone cancer in adolescents. Notwithstanding the efforts of researchers, its five-year survival …
bone cancer in adolescents. Notwithstanding the efforts of researchers, its five-year survival …
Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy
X Wang, Y Shen, X Wan, X Hu, WQ Cai, Z Wu… - Journal of Translational …, 2023 - Springer
Background Oncolytic virotherapy (OVT) is a promising anti-tumor modality that utilizes
oncolytic viruses (OVs) to preferentially attack cancers rather than normal tissues. With the …
oncolytic viruses (OVs) to preferentially attack cancers rather than normal tissues. With the …
Oncolytic Viruses and Immune Checkpoint Inhibitors: The “Hot” New Power Couple
C Lovatt, AL Parker - Cancers, 2023 - mdpi.com
Simple Summary Oncolytic viruses (OV) are engineered viruses designed to replicate
selectively within tumour cells. They hold great promise as novel cancer therapeutics, but …
selectively within tumour cells. They hold great promise as novel cancer therapeutics, but …
Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma
Gut microbiota plays a key role in modulating responses to cancer immunotherapy in
melanoma patients. Oncolytic viruses (OVs) represent emerging tools in cancer therapy …
melanoma patients. Oncolytic viruses (OVs) represent emerging tools in cancer therapy …
Systems biology approaches for the improvement of oncolytic virus-based immunotherapies
L Tripodi, E Sasso, S Feola, L Coluccino, M Vitale… - Cancers, 2023 - mdpi.com
Simple Summary This review provides a roadmap to develop safe and effective OV-based
future therapeutics by using several novel synthetic and system biology strategies …
future therapeutics by using several novel synthetic and system biology strategies …
A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity
S Mei, S Peng, EG Vong, J Zhan - International Immunopharmacology, 2024 - Elsevier
Background Clinical data indicate that a substantial portion of cancer patients, though
eligible for immune checkpoint inhibitor (ICI) therapy, cannot fully benefit from ICI …
eligible for immune checkpoint inhibitor (ICI) therapy, cannot fully benefit from ICI …
Personalizing oncolytic virotherapy
The use of oncolytic viruses has become an attractive tool in the clinics for the treatment of
various tumor types. Such viruses are genetically modified to conditionally replicate in …
various tumor types. Such viruses are genetically modified to conditionally replicate in …
[HTML][HTML] The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade
S Najafi, J Majidpoor, K Mortezaee - Biomedicine & Pharmacotherapy, 2023 - Elsevier
Immunotherapy has revolutionized treatment of cancer during the last decades. Oncolytic
virotherapy has also emerged as a strategy to fight against cancer cells both via lysis of …
virotherapy has also emerged as a strategy to fight against cancer cells both via lysis of …
Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses
ABSTRACT Introduction Oncolytic adenoviruses (Ads) are promising therapeutics to
enhance anti-tumor immune responses and modulate the immune-suppressive tumor …
enhance anti-tumor immune responses and modulate the immune-suppressive tumor …
[HTML][HTML] Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer
The programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) immune checkpoint
constitutes an inhibitory pathway best known for its regulation of cluster of differentiation 8 …
constitutes an inhibitory pathway best known for its regulation of cluster of differentiation 8 …